PTC Therapeutics completed its acquisition of ST-920 from Sangamo Therapeutics. ST-920 is a one-time administered AAV gene therapy candidate for Fabry disease, currently at the BLA stage. The company expects to complete a rolling submission to the FDA for accelerated approval in the fourth quarter of 2026. This development expands PTC's pipeline with a potential durable treatment that could reduce reliance on chronic enzyme replacement therapy. PTC Therapeutics is a global biopharmaceutical company focused on discovering and commercializing medicines for rare disorders.
